Diversified Healthcare Trust (DHC) FinancialsDHCDiversified Healthcare Trust

Diversified Healthcare Trust (DHC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is SHOP, accounting for 84.9% of total sales, equivalent to $328.31M. Other significant revenue streams include medicalOffice and life science Portfolio and Non-Segment. Understanding this composition is critical for investors evaluating how DHC navigates market cycles within the Specialized REITs industry.

Evaluating the bottom line, Diversified Healthcare Trust maintains a gross margin of -11.12%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -0.14%, while the net margin is -10.24%. These profitability ratios, combined with a Return on Equity (ROE) of -15.47%, provide a clear picture of how effectively DHC converts its operational activities into shareholder value.

In the context of the broader market, DHC competes directly with industry leaders such as BFS and NXRT. With a market capitalization of $1.87B, it holds a leading position in the sector. When comparing efficiency, DHC's gross margin of -11.12% stands against BFS's 69.22% and NXRT's 62.12%. Such benchmarking helps identify whether Diversified Healthcare Trust is trading at a premium or discount relative to its financial performance.

DHC has shown inconsistent financial performance, with a negative net income of $43.3 million in Q1 2026 and a gross margin that has turned negative in recent quarters, reaching -11.12% in Q2 2026. The company has also faced declining revenues, with Q2 2026 revenue at $365.4 million, down from previous quarters.